

February 1, 2024

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
--	--

Dear Sir/ Madam,

**Sub.: Reply to Clarification sought on news item appearing in "Media/Publication".**

**Ref. : Letter Ref. No.: NSE/CM/Surveillance/13908 dated February 1, 2024 received from NSE.**

**Letter Ref.No. L/SURV/ONL/RV/VK/ (2023-2024)/ 96 received from BSE.**

In response to your above referred letter received through e-mail on February 1, 2024 regarding recent news item which appeared in the www.cnbctv18.com dated February 01, 2024 captioned "Aurobindo Pharma's Unit 4 currently being inspected by USFDA", we would like to inform that:

- US FDA inspection of Eugia-III (erstwhile unit IV of Aurobindo Pharma Limited), a Formulation manufacturing facility, of Eugia Pharma Specialities Ltd. is under progress from January 22, 2024 and has not been concluded yet.
- As per the usual and standard practice, after the inspection is concluded, Aurobindo Pharma Limited intimates the stock exchanges regarding the outcome, including the number of observations, if any, and the same will be followed for the on-going inspection also.
- The Company has been diligently disclosing all the material information as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation 2015, in the past and confirms to disclose any material information required to be disclosed as and when it is required.

Trust this clarifies your query adequately and we shall be glad to provide any further information/ clarification that you may require.

Please take the above information on record.

Thanking you,

Yours faithfully,

For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.

Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad -500038 T.S., INDIA Tel: +91 4023736370/23747340 Fax: +91 4023741080/23746833

Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)